SLC44A3-AS1: A protein involved in cell transport and nervous system

Target Name: SLC44A3-AS1

NCBI ID: G101928079

SLC44A3-AS1

Other Name(s): XLOC_000303 | SLC44A3-AS1 variant 1 | SLC44A3 antisense RNA 1 | SLC44A3 antisense RNA 1, transcript variant 1 | LINC01057

SLC44A3-AS1: A protein involved in cell transport and nervous system

SLC44A3-AS1 (XLOC_000303) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is solute carrier family 44 member 3, asso, and it is a member of the Aspara family. The protein is involved in the transport of various substances in and out of cells, including amino acids, nucleotides, and other small molecules.

One of the unique features of SLC44A3-AS1 is its expression pattern. It is highly expressed in the brain, where it is found in the basal ganglia, the motor neurons, and the cerebral cortical regions. It is also expressed in the heart, where it is found in the cardiac muscle and the myocardium. Additionally, it is expressed in the kidneys, where it is found in the glomeruli and the interstitial cells.

SLC44A3-AS1 functions as a transporter for several different substances. It is a carrier for the neurotransmitter dopamine, which is involved in the transmission of signals in the brain. It is also a carrier for the amino acid taurine, which is involved in the regulation of muscle strength and function. Additionally, it is a carrier for the nucleotides ADP and GTP, which are involved in the regulation of intracellular signaling.

SLC44A3-AS1 is also expressed in various diseases, including Alzheimer's disease, Parkinson's disease, and heart failure. It is thought to be involved in the progression of these diseases, as it has been shown to be decreased in the brains and hearts of individuals with these conditions.

Due to its involvement in the regulation of various signaling pathways, SLC44A3-AS1 is a promising drug target. Studies have shown that blocking the function of SLC44A3-AS1 has been effective in treating various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and heart failure.

In addition to its potential therapeutic uses, SLC44A3-AS1 is also a valuable biomarker for the diagnosis of various neurological and psychiatric disorders. The expression of SLC44A3-AS1 has been shown to be decreased in the brains and hearts of individuals with Alzheimer's disease and Parkinson's disease, which is suggestive that these proteins may be useful for the diagnosis of these conditions. Additionally, the expression of SLC44A3-AS1 has been shown to be decreased in the hearts of individuals with heart failure, which is suggestive that this protein may be useful for the diagnosis of this condition.

In conclusion, SLC44A3-AS1 is a protein that is involved in the transport of various substances in and out of cells. Its expression pattern is highly influenced by the tissues in which it is expressed, and it functions as a transporter for several different substances, including neurotransmitters and nucleotides. Its involvement in the regulation of various signaling pathways makes it a promising drug target for the treatment of various neurological and psychiatric disorders. Additionally, its expression has also been shown to be decreased in the brains and hearts of individuals with Alzheimer's disease, Parkinson's disease, and heart failure, which makes it a valuable biomarker for the diagnosis of these conditions. Further research is needed to fully understand the role of SLC44A3-AS1 in the regulation of various signaling pathways and its potential as a drug target and biomarker.

Protein Name: SLC44A3 Antisense RNA 1

The "SLC44A3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC44A3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets